Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Cardiology
•
Advanced Heart Failure and Transplant
How do you use NT-proBNP in patients with chronic kidney disease or end-stage kidney disease, given that these conditions can affect NT-proBNP levels?
Related Questions
For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?
Do you recommend avoiding ESAs in ESKD patients with heart failure who require a left ventricular assist device?
How do you weigh the benefit of urinary catheter placement for strict I/O measurement with the risk of avoidable CAUTI?
Is there a role for aspirin 81 mg daily in patients with nonischemic dilated cardiomyopathy with reduced EF?
For patients acutely decompensated with ACC Stage C-D, NYHA 3-4, probable INTERMACS 4, how do you decide between MCS devices like CCM Barostim or potentially LVAD?
How long do you wait before starting a non-selective beta blocker in patients with newly reduced LVEF and recent cocaine use?
How do you decide on the speed and target of blood pressure reduction for spontaneous intracranial hemorrhage?
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
Do you recommend initiating treatment with an SGLT2 inhibitor or semaglutide first for a patient with obesity and heart failure with preserved ejection fraction?
Would you ever consider switching a patient with an LVAD from warfarin to Eliquis, such as in the setting of recurrent GI bleeds?
